Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia - Stein, Andrew M.; Müller, Martin Christian (BMC cancer, 2013)
Gesehen am: 21.01.2015